Introduction {#s1}
============

Type 1 diabetes is a significant public health problem because of its early onset, progressive course, and high rate of complications including retinopathy, nephropathy, neuropathy, and cardiovascular disease ([@B1]). Less studied are urological conditions associated with diabetes such as sexual dysfunction, urinary tract infection (UTI), poor bladder emptying, urinary incontinence (UI), and other lower urinary tract symptoms (LUTS) that often initiate care seeking and negatively impact quality of life ([@B2],[@B3]). Studies have shown that a number of these specific urological complications are associated with more severe and less controlled type 1 diabetes; however, reports are based on singular complications and whether they co-occur with each other is unknown ([@B4]--[@B9]).

For better characterization of the burden of individual and cumulative urological complications in persons with type 1 diabetes, the Urologic EDIC, or UroEDIC, study was established as an ancillary study to the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the observational follow-up to the Diabetes Control and Complications Trial (DCCT). The UroEDIC protocol included a series of well-validated urological symptom questionnaires self-administered to women and men in one of the largest and longest-running clinical studies of type 1 diabetes. We describe findings from two surveys obtained 7 years apart to document the prevalence and co-occurrence of sexual dysfunction, UI, LUTS, and UTI, as well as their rates of emergence, persistence, and remission. In addition, we identify associations between these urological complications and demographic and clinical diabetes-related variables. Findings from the UroEDIC ancillary study may provide accurate information to health care providers, patients, and families about traditionally embarrassing urological health problems and could be used to develop risk factor models for specific urological complications among persons with type 1 diabetes.

Research Design and Methods {#s2}
===========================

A total of 1,441 subjects were recruited into the DCCT and randomized to two interventions: intensive insulin therapy or conventional therapy. Intensive therapy was aimed at achieving normal glycemic levels using three or more daily insulin injections or continuous subcutaneous insulin infusion with dose adjustments based on frequent self-monitoring of blood glucose, while conventional therapy was aimed at maintaining clinical well-being with one to two daily insulin injections with no specified glucose targets ([@B10],[@B11]). Two parallel cohorts were recruited: a primary prevention cohort (with 1--5 years' diabetes duration, no retinopathy, and urine albumin excretion rate \[AER\] of \<40 mg/24 h) and a secondary intervention cohort (1--15 years' duration, mild to moderate nonproliferative diabetic retinopathy, and AER ≤200 mg/24 h). After a mean follow-up of 6.5 years, the DCCT ended early in 1993 when the principal study question concerning treatment effects was answered. Intensive insulin treatment was found to dramatically delay the onset and slow the progression of retinopathy, nephropathy, and neuropathy by 35 to \>70% ([@B10]). In 1994, 96% of the original DCCT cohort agreed to participate in EDIC, which includes annual examinations for complication status ([@B11]). The mean age of the participants at EDIC baseline was 33.6 years, with a mean duration of diabetes of 12.2 years.

All men and women enrolled in EDIC were invited to participate in UroEDIC at EDIC year 10 (2003 \[UroEDIC I\]) and again at EDIC year 17/18 (2010/2011 \[UroEDIC II\]) irrespective of participation at year 10. There was a net increase in participation from UroEDIC I to UroEDIC II. Consenting participants completed a confidential survey assessing sexual and urinary function, symptom impact, and history of UTI. The Human Subjects Division of the University of Washington approved a central study protocol, and the institutional review board of each participating clinical center approved the UroEDIC I and II protocols.

Measures of Urological Complications {#s3}
------------------------------------

Primary outcome variables were designated a priori for each urological complication based on established cut points for items derived from widely used, well-validated, and reliable instruments as outlined below.

### Male Sexual Dysfunction {#s4}

Erectile function, sexual desire, and orgasmic function were assessed by responses to items selected from the International Index of Erectile Function ([@B12]). Erectile function was dichotomized using a single-item proxy: "Over the past 4 weeks, how would you rate your confidence that you get and keep your erection?" If the participant answered "very low" (1) or "low" (2), they were considered to have erectile dysfunction (ED), and if "moderate" (3), "high" (4), or "very high" (5) they were considered to have no ED. This definition had a strong correlation with total erectile function domain scores and degree of bother related to ED ([@B7]). In addition, men reporting sildenafil citrate in the annual survey after EDIC year 10 or reporting any oral phosphodiesterase type 5 inhibitor (sildenafil, vardenafil, tadalafil) or other treatment (urethral suppositories, penile injections or implants, vacuum erection devices) at year 17/18 were considered to have ED. Low sexual desire (LD) and orgasmic dysfunction (OD) were defined as a score \<7 on the respective 10-point Desire and Orgasm domains of the International Index of Erectile Function ([@B12]).

### Female Sexual Dysfunction {#s5}

Sexual function in women was assessed by means of an abbreviated version of the Female Sexual Function Index (FSFI-R), which included 7 of the 19 original FSFI items and scored as a total sum of all the items representing each domain of sexual functioning as well as the mean score of two items assessing satisfaction. The primary outcome variable defines the presence of female sexual dysfunction (FSD) as a score equal to or above the cutoff value of 22.75 on the total scale score. This has been shown to be equivalent to the full-scale measure ([@B9]). As with the full survey instrument, only sexually active women are included in the analyses.

### UI {#s6}

UI in women was assessed based on frequency and amount of urine lost per episode (drops, small splashes, more) using the Sandvik Severity Index ([@B13]). Calculated from frequency and amount of urine loss on a scale of 1--12 (mild 1--2, moderate 3--6, severe 8--9, very severe 10--12), the primary outcome was moderate (≥3) or more severe UI.

### LUTS {#s7}

LUTS, including nocturia, frequency, urgency, weak urinary stream, intermittency, straining, and the sensation of incomplete emptying, were assessed in men and women using the American Urological Association Symptom Index ([@B14]). Following widely accepted cut points of 0--7, 8--19, and 20--35 designated as none/mild, moderate, and severe LUTS, respectively, we dichotomized responses into no LUTS (0--7) versus LUTS (8--35).

### UTI {#s8}

UTI was assessed with questions asking "How many times in the last 12 months were you diagnosed with a bladder infection?" and, separately, "a kidney infection?" For the purpose of analysis, an answer of zero was considered a negative response, while an answer of one or more bladder or kidney infection(s) was considered a positive response.

Measures of Secondary Factors {#s9}
-----------------------------

### Glycemic Control and Microvascular Complications {#s10}

HbA~1c~ was measured at baseline and quarterly during DCCT and annually in EDIC ([@B11]). The DCCT/EDIC time-weighted arithmetic mean HbA~1c~ was calculated using quarterly DCCT and annual EDIC values weighted by 3 and 12 months, respectively ([@B11],[@B15]). A time-weighted BMI was calculated in the same manner. Peripheral neuropathy was defined during EDIC by more than six positive responses on the Michigan Neuropathy Screening Instrument (MNSI) or a score \>2 on the MNSI examination ([@B16]). Autonomic neuropathy was defined as follows: either R-R variation \<15 or R-R variation between 15 and 19.9 plus either a Valsalva ratio ≤1.5 or a supine-to-standing drop in diastolic blood pressure of 10 mmHg. Retinopathy was assessed using fundus photographs that were centrally graded using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale ([@B17]). AER was measured in half of the cohort annually during EDIC. Nephropathy was defined as microalbuminuria (AER 40--300 mg/24 h) or albuminuria (AER \>300 mg/24 h).

Statistical Methods {#s11}
-------------------

Prevalence of urological complications was calculated at EDIC years 10 (UroEDIC I) and 17/18 (UroEDIC II). Emergence, persistence, and remission of urological complications were estimated as follows: emergence was defined as subjects being free of a complication at UroEDIC I but positive at UroEDIC II, persistence was defined as subjects having a complication at UroEDIC I and II, and remission was defined as subjects being positive at UroEDIC I but free of a complication at UroEDIC II. The classification of positive and negative for each complication was based on symptom scores crossing predefined thresholds. Logistic regression models were used to examine the associations between binary urological complication classifications and sociodemographic and diabetes-related characteristics. Associations were estimated using odds ratios and their respective 95% CIs. All analyses were performed using SAS, version 8.2 (SAS Institute, Cary, NC).

Results {#s12}
=======

Participation rates of active EDIC participants in UroEDIC I and UroEDIC II surveys were 83.6 and 95.1%, respectively. Of the 1,141 participants who completed UroEDIC I, 1,059 (92.8%) participated in UroEDIC II. The number of study participants in DCCT, EDIC, and UroEDIC is shown in [Fig. 1](#F1){ref-type="fig"}. Among UroEDIC study participants who completed either survey, specific item completion rates ranged from 92 to 99%, depending on complication type.

![Study cohort diagram. Flow of participants through the study from DCCT to EDIC and UroEDIC I and II. There were a greater number of participants (1,224) in UroEDIC II compared with UroEDIC I (1,141). \*Enrollees were asked to take part in UroEDIC II irrespective of participation in UroEDIC I. There was a net increase in participation from UroEDIC I to UroEDIC II.](dc180255f1){#F1}

A total of 508 women and 551 men completed surveys at both time points of the study. The prevalence and subsequent emergence, persistence, and remission of urological complications over the 7-year period were assessed ([Table 1](#T1){ref-type="table"}). The majority of participants with a urological complication at UroEDIC I had persistence of that same complication at UroEDIC II (range of 56--86%) with the exception of UTI in females, where only 29% of those reporting the complication at the first survey reported a bladder or kidney infection during the second survey. At UroEDIC II, the proportion of those reporting specific complications that were not present at year 10 ranged from 42 to 63% with the exception of UTI in women, where 73% reported the complication for the first time. In men, age was associated with emergence of LUTS (\<0.01) and persistence of all four complications: LUTS (\<0.001), ED (\<0.0001), LD (\<0.01), and OD (0.0063). HbA~1c~ was associated with persistence of ED (\<0.0001) and persistence of OD (\<0.001). In women, age was associated with emergence of FSD (0.03) and persistence of FSD (\<0.001) and UI (0.03). HbA~1c~ was associated with emergence of LUTS (0.03) and persistence of UI (0.05). Treatment group was not associated with emergence or persistence of complications (data not shown).

###### 

Prevalence and change in urological complication status in women and men who completed both UroEDIC I and II surveys at EDIC years 10 and 17/18

                                        Respondents within entire cohort   Prevalence in UroEDIC I[\*](#t1n1){ref-type="table-fn"}   Prevalence in UroEDIC II[\*](#t1n1){ref-type="table-fn"}   Emergence at follow-up   Persistence at follow-up   Remission at follow-up
  ------------------------------------- ---------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ------------------------ -------------------------- ------------------------
  Women                                 508                                                                                                                                                                                                         
   LUTS                                 506 (99)                           101 (20)                                                  113 (22)                                                   52 (10)                  61 (12)                    40 (8)
   FSD[†](#t1n2){ref-type="table-fn"}   297 (58)                           98 (33)                                                   125 (42)                                                   53 (18)                  72 (24)                    26 (9)
   UI                                   493 (97)                           109 (22)                                                  151 (31)                                                   81 (16)                  70 (14)                    39 (8)
   UTI                                  468 (92)                           75 (16)                                                   80 (17)                                                    58 (12)                  22 (5)                     53 (11)
  Men                                   551                                                                                                                                                                                                         
   LUTS                                 550 (99)                           100 (18)                                                  132 (24)                                                   70 (13)                  62 (11)                    38 (7)
   ED[‡](#t1n3){ref-type="table-fn"}    525 (95)                           129 (25)                                                  238 (45)                                                   126 (24)                 112 (21)                   17 (3)
   LD                                   506 (92)                           182 (36)                                                  203 (40)                                                   94 (19)                  109 (22)                   73 (14)
   OD                                   461 (84)                           41 (9)                                                    63 (14)                                                    40 (9)                   23 (5)                     18 (4)

Data are *N* or *N* (% of respondents). Emergence defined as subjects being free of disorder at UroEDIC I but positive at UroEDIC II. Persistence defined as subjects being positive at UroEDIC I and positive at UroEDIC II. Remission defined as subjects being positive at UroEDIC I but free of disorder at UroEDIC II.

\*UroEDIC I completed at EDIC year 10 and UroEDIC II completed at EDIC year 17/18.

†FSD only assessed in sexually active women per FSFI scoring algorithm.

‡ED at UroEDIC I includes men who were using sildenafil citrate based on self-report. ED at UroEDIC II includes men using any oral medications, urethral suppositories, intracavernosal injections, penile implants, or vacuum erection devices.

Overall, 65% of women and 68% of men reported at least one urological complication at UroEDIC II. The prevalence of the urological complications at UroEDIC II for women was LUTS 22%, FSD 42%, UI 31%, and UTI 17% and for men LUTS 24%, ED 45%, LD 40%, and OD 14%. The overlap and cumulative total of prevalent urological complications for respondents who had data for all urological complications at UroEDIC II are shown in [Fig. 2*A*](#F2){ref-type="fig"} (women) and [Fig. 2*B*](#F2){ref-type="fig"} (men). Of note, because FSD was assessed only in sexually active women, the proportion of patients with overlap between FSD and other urological complications was calculated based on the smaller denominator of sexually active women. Overall, in sexually active women, 35% reported no complications, 39% had one, and 26% had two or more other complications. The pattern of overlap in women differed across the specific urological complications: more commonly LUTS co-occurred with other complications and FSD occurred in isolation. In men, 31% had no complications, 36% had one, and 33% had two or more. Similarly, the pattern of overlap in men was specific to each complication, with LUTS occurring more commonly in isolation of other complications, while ED, LD, and OD co-occurred.

![*A*: Prevalence of urological complications in women at UroEDIC II. *B*: Prevalence of urological complications in men at UroEDIC II. Overlap of number of participants with specific complications and cumulative complication occurrence among women (*A*) and men (*B*) who completed UroEDIC II. In *A*, only women who were sexually active could be scored with the FSFI, reducing total number of participants included in the figure. Overlap of other complications was similar for women who were not sexually active (data not shown). Size of diagrams not proportional to number of participants with each complication. \*FSD excluded in complication count. †Respondents had data available for all four complications.](dc180255f2){#F2}

We analyzed the cohort by sex to identify demographic, glycemic control, and microvascular complication variables associated with urological complications at UroEDIC II. In women ([Table 2](#T2){ref-type="table"}), increasing age was positively associated with FSD and UI. Women in the highest quartile of HbA~1c~ (\>8.54%) were two times more likely to report LUTS compared with those in the lowest quartile of HbA~1c~ (≤7.38%). Additionally, BMI ≥30 kg/m^2^ was associated with a higher odds of reporting UI. Women with nephropathy had a higher odds of reporting UTI, those with peripheral neuropathy had a higher odds of LUTS, and those with autonomic neuropathy had higher odds of FSD and UTI. In men ([Table 3](#T3){ref-type="table"}), increasing age was positively associated with LUTS, ED, and OD. Participants in higher HbA~1c~ quartiles had a higher odds of reporting ED and OD. BMI was not observed to be an independent risk factor for male urological complications. Men with any measured diabetes-related microvascular complications had a higher odds of reporting LUTS, ED, and OD. Complication prevalence was not associated with DCCT intensive insulin therapy versus conventional therapy.

###### 

Unadjusted odds of urological complications in women at UroEDIC II by demographic, clinical, and diabetes-related complication categories

                                                                         LUTS                    FSD                       UI                       UTI
  ----------------------------------------------------------- ---------- ----------------------- ------------------------- ------------------------ -----------------------
  *N* total respondents                                       580        579                     371                       571                      555
  *N* (%) with complication                                              128 (22)                153 (41)                  172 (30)                 95 (17)
  Age quartiles (years)                                                                                                                             
   30--39                                                     35 (6)     Reference               Reference                 Reference                Reference
   40--49                                                     230 (40)   1.95 (0.66--5.80)       2.53 (0.92--6.98)         **4.67 (1.38--15.78)**   0.77 (0.31--1.92)
   50--59                                                     238 (41)   2.73 (0.93--8.05)       **4.27 (1.54--11.85)**    **4.91 (1.46--16.56)**   0.63 (0.25--1.56)
   60--69                                                     77 (13)    2.03 (0.63--6.60)       **10.91 (3.30--36.08)**   **4.48 (1.24--16.16)**   0.88 (0.32--2.41)
  BMI (kg/m^2^)                                                                                                                                     
   \<25                                                       153 (28)   Reference               Reference                 Reference                Reference
   25--30                                                     220 (40)   1.08 (0.65--1.81)       1.19 (0.71--1.99)         1.26 (0.78--2.03)        1.42 (0.81--2.50)
   ≥30                                                        177 (32)   1.58 (0.94--2.66)       0.91 (0.52--1.61)         **2.27 (1.40--3.68)**    1.00 (0.54--1.84)
  Enrollment cohort                                                                                                                                 
   Secondary intervention                                     293 (51)   Reference               Reference                 Reference                Reference
   Primary prevention                                         287 (49)   1.10 (0.75--1.63)       0.90 (0.59--1.36)         0.83 (0.58--1.18)        1.00 (0.64--1.55)
  Treatment group                                                                                                                                   
   Conventional                                               303 (52)   Reference               Reference                 Reference                Reference
   Intensive                                                  277 (48)   1.09 (0.73--1.61)       1.22 (0.81--1.85)         1.22 (0.85--1.75)        0.79 (0.51--1.23)
  HbA~1c~ quartiles, %                                                                                                                              
   ≤7.38                                                      138 (25)   Reference               Reference                 Reference                Reference
   \>7.38--7.92                                               141 (25)   1.71 (0.95--3.08)       1.14 (0.63--2.06)         1.00 (0.60--1.68)        0.70 (0.34--1.45)
   \>7.92--8.54                                               138 (25)   1.22 (0.66--2.25)       1.09 (0.60--1.97)         0.91 (0.54--1.53)        1.52 (0.80--2.88)
   \>8.54                                                     138 (25)   **2.06 (1.16--3.68)**   0.92 (0.50--1.68)         1.15 (0.69--1.91)        1.72 (0.91--3.25)
  Retinopathy[\*](#t2n1){ref-type="table-fn"}                                                                                                       
   No retinopathy                                             51 (9)     Reference               Reference                 Reference                Reference
   Microaneurysms                                             215 (37)   0.89 (0.42--1.88)       1.39 (0.65--2.99)         1.26 (0.62--2.57)        1.14 (0.47--2.75)
   Mild/moderate NPDR                                         216 (37)   1.04 (0.50--2.18)       1.42 (0.66--3.05)         1.44 (0.71--2.94)        1.24 (0.52--2.98)
   PDR or worse                                               98 (17)    1.38 (0.62--3.08)       2.23 (0.95--5.27)         1.66 (0.77--3.60)        1.24 (0.47--3.25)
  Nephropathy (AER, mg/24 h)[†](#t2n2){ref-type="table-fn"}                                                                                         
   None (\<30)                                                460 (84)   Reference               Reference                 Reference                Reference
   Microalbuminuria (30--300)                                 79 (14)    1.50 (0.87--2.58)       0.68 (0.36--1.28)         1.12 (0.67--1.89)        **2.08 (1.17--3.69)**
   Macroalbuminuria (≥300)                                    11 (2)     2.23 (0.64--7.76)       1.05 (0.23--4.76)         0.23 (0.03--1.85)        2.86 (0.70--11.70)
  Peripheral neuropathy[‡](#t2n3){ref-type="table-fn"}                                                                                              
   Normal MNSI                                                324 (59)   Reference               Reference                 Reference                Reference
   Abnormal MNSI                                              228 (41)   **1.80 (1.21--2.69)**   1.47 (0.94--2.29)         1.00 (0.69--1.45)        1.56 (0.99--2.46)
  Autonomic neuropathy[§](#t2n4){ref-type="table-fn"}                                                                                               
   No                                                         333 (61)   Reference               Reference                 Reference                Reference
   Yes                                                        216 (39)   1.28 (0.85--1.92)       **1.67 (1.07--2.60)**     1.28 (0.88--1.85)        **1.57 (1.00--2.47)**

Data are *N* (%) or unadjusted odds ratios (95% CI) unless otherwise indicated. Significant values are in boldface type. NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

\*Retinopathy defined through EDIC year 14 using the ETDRS scale of 0--23.

†Nephropathy defined at EDIC year 15/16.

‡Peripheral neuropathy defined at EDIC year 17 by the MNSI: \>6 responses on the questionnaire or a score of \>2 on exam.

§Autonomic neuropathy defined at EDIC year 16/17 as an R-R variation \<15 or R-R variation \<20 in combination with a Valsalva ratio ≤1.5 or a decrease of \>10 mmHg in diastolic blood pressure upon standing.

###### 

Unadjusted odds of urological complications in men at UroEDIC II by demographic, clinical, and diabetes-related complication categories

                                                                         LUTS                     ED                         LD                  OD
  ----------------------------------------------------------- ---------- ------------------------ -------------------------- ------------------- -----------------------
  *N* total respondents                                       644        643                      635                        598                 564
  *N* (%) with complication                                              158 (25)                 290 (46)                   243 (41)            83 (15)
  Age quartiles (years)                                                                                                                          
   30--39                                                     30 (5)     Reference                Reference                  Reference           ---
   40--49                                                     201 (31)   1.28 (0.42--3.92)        4.30 (1.26--14.73)         1.16 (0.50--2.71)   Reference
   50--59                                                     336 (52)   2.20 (0.75--6.49)        **8.31 (2.47--27.98)**     1.51 (0.66--3.44)   1.52 (0.88--2.64)
   60--69                                                     77 (12)    **5.71 (1.82--17.92)**   **30.08 (8.11--111.61)**   2.46 (0.97--6.25)   **2.49 (1.17--5.28)**
  BMI (kg/m^2^)                                                                                                                                  
   \<25                                                       132 (21)   Reference                Reference                  Reference           Reference
   25--30                                                     268 (43)   0.81 (0.51--1.30)        0.91 (0.60--1.39)          0.58 (0.38--0.90)   0.82 (0.43--1.55)
   ≥30                                                        228 (36)   0.72 (0.44--1.18)        1.35 (0.87--2.07)          0.80 (0.51--1.25)   1.12 (0.59--2.13)
  Enrollment cohort                                                                                                                              
   Secondary intervention                                     320 (50)   Reference                Reference                  Reference           Reference
   Primary prevention                                         324 (50)   1.01 (0.71--1.45)        0.69 (0.50--0.94)          0.96 (0.69--1.33)   0.93 (0.58--1.28)
  Treatment group                                                                                                                                
   Conventional                                               320 (50)   Reference                Reference                  Reference           Reference
   Intensive                                                  324 (50)   0.89 (0.62--1.28)        0.95 (0.95--0.70)          0.97 (0.70--1.34)   0.91 (0.57--1.45)
  HbA~1c~ quartiles, %                                                                                                                           
   ≤7.25                                                      157 (25)   Reference                Reference                  Reference           Reference
   \>7.25--7.85                                               158 (25)   0.99 (0.59--1.68)        1.33 (0.84--2.10)          1.06 (0.67--1.69)   1.62 (0.79--3.34)
   \>7.85--8.58                                               160 (25)   1.20 (0.72--2.00)        **1.60 (1.02--2.51)**      0.91 (0.57--1.45)   1.39 (0.66--2.92)
   \>8.58                                                     157 (25)   1.08 (0.64--1.82)        **2.74 (1.73--4.35)**      1.10 (0.69--1.75)   **2.69 (1.35--5.35)**
  Retinopathy[\*](#t3n1){ref-type="table-fn"}                                                                                                    
   No retinopathy                                             43 (7)     Reference                Reference                  Reference           Reference
   Microaneurysms                                             204 (32)   0.53 (0.26--1.07)        0.96 (0.49--1.90)          0.67 (0.34--1.32)   0.83 (0.29--2.36)
   Mild/moderate NPDR                                         267 (41)   0.55 (0.28--1.10)        1.66 (0.86--3.23)          0.81 (0.42--1.59)   1.13 (0.41--3.11)
   PDR or worse                                               130 (20)   0.75 (0.36--1.56)        **2.11 (1.04--4.30)**      0.72 (0.35--1.49)   1.39 (0.48--4.03)
  Nephropathy (AER, mg/24 h)[†](#t3n2){ref-type="table-fn"}                                                                                      
   None (\<30)                                                475 (77)   Reference                Reference                  Reference           Reference
   Microalbuminuria (30--300)                                 104 (17)   **1.86 (1.17--2.97)**    **2.83 (1.80--4.43)**      1.28 (0.81--2.04)   **2.44 (1.35--4.42)**
   Macroalbuminuria (≥300)                                    40 (6)     **2.56 (1.31--5.00)**    1.63 (0.85--3.12)          0.82 (0.41--1.65)   **3.50 (1.62--7.56)**
  Peripheral neuropathy[‡](#t3n3){ref-type="table-fn"}                                                                                           
   Normal MNSI                                                360 (57)   Reference                Reference                  Reference           Reference
   Abnormal MNSI                                              270 (43)   **1.97 (1.36--2.84)**    **2.15 (1.55--2.97)**      1.21 (0.87--1.69)   **2.25 (1.39--3.64)**
  Autonomic neuropathy[§](#t3n4){ref-type="table-fn"}                                                                                            
   No                                                         391 (63)   Reference                Reference                  Reference           Reference
   Yes                                                        234 (37)   **2.07 (1.42--3.01)**    **2.82 (2.01--3.94)**      1.28 (0.91--1.80)   **2.40 (1.49--3.88)**

Data are *N* (%) or unadjusted odds ratios (95% CI) unless otherwise indicated. Significant values are in boldface type. NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

\*Retinopathy defined through EDIC year 14 using the ETDRS scale of 0--23.

†Nephropathy defined at EDIC year 15/16.

‡Peripheral neuropathy defined at EDIC year 17 by the MNSI: \>6 responses on the questionnaire or a score of \>2 on exam.

§Autonomic neuropathy defined at EDIC year 16/17 as an R-R variation \<15 or R-R variation \<20 in combination with a Valsalva ratio ≤1.5 or a decrease of \>10 mmHg in diastolic blood pressure upon standing.

Conclusions {#s13}
===========

Urological morbidity associated with diabetes results from metabolic effects on genitourinary tissues and the neural, vascular, and hormonal input to these organs. With a reported 65.5% prevalence of at least one urological complication, these complications pose a significant burden on this cohort of middle-aged patients with type 1 diabetes compared with population-based surveys with considerably lower reported prevalence ([@B18]--[@B21]). In addition, observed urological complications co-occurred significantly more than would be expected were these independent complications (e.g., tests for concordance of independence \[data not shown\]). Presumably, the overlap of symptom complexes reflects shared mechanisms, conditioning of responses across complications, or other factors. The impact of both singular and co-occurring sexual and urinary dysfunctions on quality of life, health perception, and depression, although beyond the scope of this report, has been shown to be negatively associated independent of diabetes complications and similar in magnitude to the impact of hypertension or diabetes itself ([@B22]). Thus, as improvements in diabetes management reduce the severity of retinopathy, nephropathy, and neuropathy, urological complications may become important drivers of quality of life ([@B23],[@B24]).

Findings in Women {#s14}
-----------------

Prevalence of FSD in this cohort is similar to that in women in the Boston Area Community Health (BACH) survey (41 and 36%, respectively) ([@B25]). FSD was strongly associated with age but not glycemic control or diabetes complications, confirming earlier findings in this and other cohorts ([@B9]). Reporting of FSD as a single complication was more common compared with the other urological complications, supporting a separate etiological mechanism from UI, LUTS, and UTI. Prior publications including findings from UroEDIC I show depression to be the major factor associated with FSD ([@B9]).

The second most prevalent urological complication reported in women participants of UroEDIC was UI, which can lead to significant distress, social isolation, and poorer quality of life ([@B25],[@B26]). In the current study, 31% of women reported weekly or greater UI. The comparable rates in women in their forties are 15% in BACH and 17% in the National Health and Nutrition Examination Survey (NHANES) ([@B26],[@B27]). For LUTS, differences were less striking (22% in UroEDIC vs. 17% in BACH) ([@B22]). The association of UI with BMI replicates findings in populations without diabetes and women with type 2 diabetes ([@B28]--[@B30]). Further studies in the UroEDIC cohort offer the opportunity to investigate the effects of aging, glycemia, and other diabetes complications such as peripheral or autonomic neuropathy on the onset of UI as this population ages. Of note, a third of women with UI also reported LUTS ([Fig. 2](#F2){ref-type="fig"})---a subset that requires further investigation.

UTI prevalence did not differ substantially from previously reported population-based estimates such as NHANES ([@B5]). It is notable that women with autonomic neuropathy exhibited increased odds of UTI, which could reflect poor bladder emptying due to diabetic cystopathy. In a recent more detailed analysis, we demonstrated an association between UTI and higher HbA~1c~ levels ([@B31]). Forty percent of the participants reporting UTI also reported either UI or LUTS, suggesting potential overlap in etiological mechanisms for these complications.

Findings in Men {#s15}
---------------

Urological complications were highly prevalent in the male participants, with 62% of men having at least one complication. ED was the most common and demonstrated predictable associations with age, poorer diabetes control, and other diabetes complications including autonomic neuropathy. The proportion of men reporting ED was much higher than in a comparable group in NHANES (e.g., 42% in UroEDIC II vs. 8% in the NHANES 40- to 50-year-old age-group) ([@B32]). LD was highly prevalent as well, despite only 9.5% of the cohort having low serum testosterone levels at UroEDIC II (data not shown). Similar to FSD, LD has a higher rate of men reporting the one complication alone and may have etiological pathways, such as depression, that are independent of metabolic, neural, and vascular mechanisms. Disorders of orgasm, including retrograde ejaculation and anejaculation, which may be signals of impaired autonomic innervation of the bladder neck or ejaculatory system, overlapped closely with ED. A potential subcohort for future investigation of mechanisms could be the two-thirds of the men reporting ED who also reported LD or OD.

One quarter of men reported moderate to severe LUTS. LUTS in males with diabetes may be partly attributed to benign prostatic hyperplasia, other related comorbidities, and relevant demographics ([@B33],[@B34]). Incident cases identified in UroEDIC II offer the potential for investigations of the interaction between benign prostatic enlargement, diabetes control, and other diabetes complications.

Remission of Urological Complications {#s16}
-------------------------------------

Few longitudinal studies of urological complication temporal patterns exist in persons with diabetes and none in women. A notable finding of the current study is remission rates in all urological complications. For incontinent episodes specifically, a small percentage of women showed reduction in occurrence between EDIC years 10 and 17. Improvements in UI were seen in a small randomized controlled trial of weight loss and exercise in obese women ([@B35]), and weight loss was the factor most highly associated with reductions in incident or prevalent UI in the Look AHEAD (Action for Health in Diabetes) and Diabetes Prevention Program (DPP) cohorts ([@B29],[@B35]--[@B38]). Remission of ED in the current study mirrors what has been reported in some population-based studies despite the fact that ED has traditionally been considered an irreversible consequence of prolonged hyperglycemia in males with diabetes ([@B39],[@B40]). LD had the highest rate of remission, reinforcing the notion that a separate mechanistic pathway may exist. Identifying factors that predict improvement in urological complications in men and women with type 1 diabetes is an important future goal for UroEDIC.

Additional analyses (data not shown) indicate that some patients had varying degrees of change in urological and sexual function complications without crossing predefined thresholds for a specific complication. Thus, some level of remission may not be accounted for in these analyses. The study was also limited by use of questionnaires to define subjective complications, missing data owing to nonparticipation, and use of unvalidated UTI questions. We were not able to assess impact of treatment for these complications on persistence and emergence. Future work is needed to determine whether the magnitudes of change are associated with increased symptom impact on quality of life. Lastly, the UroEDIC cohort represents a motivated and highly selected group of individuals; thus, findings may not be generalizable to the whole population.

Conclusion {#s17}
----------

Urological complications are prevalent and frequently coexist in men and women with type 1 diabetes. The majority of participants in the UroEDIC study demonstrate persistence of urological complications over a 7-year period, although remission in a subset offers the potential for future studies to investigate mechanisms of symptom improvement. As people with diabetes live longer and avoid other diabetes-related complications, urological complications may represent a more significant burden and impact on quality of life, as well as present an opportunity for increased symptom mitigation efforts.
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